CompletedNCT00868959
Long-term lurasidone safety for depression in bipolarity
About this title
Read the official source — NCT00868959Medication studyAges 18–75Multiple countries
Understand this study
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 150 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateApril 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 817
- Sponsor
- Sumitomo Pharma America, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Canada, ...
- Age range
- From 18 Years to 75 Years
- Official registry ID
- NCT00868959
- Official title
Show the full official title
A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedLittle Rock, United States · Anaheim, United States · Chino, United States
125 more locations
- Costa Mesa, United States
- Escondido, United States
- Garden Grove, United States
- Los Angeles, United States
- Maitland, United States
- Oceanside, United States
- Orange, United States
- Pico Rivera, United States
- Riverside, United States
- San Diego, United States
- Santa Ana, United States
- Stanford, United States
- Torrance, United States
- Aurora, United States
- Colorado Springs, United States
- Bradenton, United States
- Fruitland Park, United States
- Kissimmee, United States
- Orlando, United States
- Tampa, United States
- West Palm Beach, United States
- Rosewekk, United States
- Smyrna, United States
- Oak Brook, United States
- Lake Charles, United States
- Shreveport, United States
- Baltimore, United States
- Rockville, United States
- Flowood, United States
- Saint Charles, United States
- Willingboro, United States
- Albuquerque, United States
- Brooklyn, United States
- Cedarhurst, United States
- New York, United States
- Rochester, United States
- Raleigh, United States
- Avon Lake, United States
- Cincinnati, United States
- Cleveland, United States
- Dayton, United States
- Portland, United States
- Allentown, United States
- Memphis, United States
- Austin, United States
- Dallas, United States
- Houston, United States
- Wharton, United States
- Seattle, United States
- Edmonton, Canada
- Kelowna, Canada
- Gatineau, Canada
- Montreal, Canada
- Barranquilla, Colombia
- Bello, Colombia
- Bogotá, Colombia
- Brno - Mesto, Czechia
- Litoměřice, Czechia
- Lovosicka, Czechia
- Olomouc, Czechia
- Prague, Czechia
- Nîmes, France
- Orvault, France
- Tirupati, India
- Vijaywada, India
- Visakhapatnam, India
- Ahmedabad, India
- Vadodara, India
- Bangalore, India
- Mangalore, India
- Chhatrapati Sambhajinagar, India
- Pune, India
- Wardha, India
- Delhi, India
- Jaipur, India
- Kanpur, India
- Lucknow, India
- Gujarat, India
- Mahara, India
- Hachioji-shi, Japan
- Ichikawa-sha, Japan
- Kanzaki-gun, Japan
- Kodaira-shi, Japan
- Sakaishi, Japan
- Takatsuki-shi, Japan
- Kaunas, Lithuania
- Šilutė, Lithuania
- Vilnius, Lithuania
- Lima, Peru
- Chełmno, Poland
- Skorzewo, Poland
- Bucharest, Romania
- Cluj-Napoca, Romania
- Craiova, Romania
- Gura Ocniței, Romania
- Oradea, Romania
- Moscow, Russia
- Saint Petersburg, Russia
- Bojnice, Slovakia
- Bratislava, Slovakia
- Liptovský Mikuláš, Slovakia
- Rimavská Sobota, Slovakia
- Rožňava, Slovakia
- Svidník, Slovakia
- Trenčín, Slovakia
- Cape Town, South Africa
- Cape Town, W. Cape, South Africa
- Paarl, W. Cape, South Africa
- Port Elizabeth, South Africa
- Pretoria, Gauteng, South Africa
- Vereeniging, Free State, South Africa
- Dnipropetrovsk, Ukraine
- Donetsk, Ukraine
- Kharkiv, Ukraine
- Kherson, Ukraine
- Kviv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Poltava, Ukraine
- Simferopol, Ukraine
- Ternopil, Ukraine
- Vinnitsia, Ukraine
- Zaporizhzhya, Ukraine
- Czechia
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including lurasidone.
Who was this study for?
This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.
